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Summary
Objective: The aim of this study was to investigate cochlear damage in Crimean—Congo
hemorrhagic fever (CCHF) infection.
Methods: Thirty-two CCHF patients (study group) and 13 healthy people (controls) were included
in the study. CCHF patients were also grouped for the presence of fever. CCHF was diagnosed with
the presence of CCHF virus-specific IgM antibody or CCHF virus (CCHFV) antigen by ELISA.
Cochlear damage was determined by a ‘fail’ in the transient evoked otoacoustic emission
(TEOAE) test.
Results: The proportion of TEOAE test ‘fail’ results in the CCHF patients was significantly higher
than in the control group (p < 0.05). We found no increase in the proportion of TEOAE test ‘fail’
results related to fever in the study group.
Conclusions: CCHF disease damages cochlear function regardless of fever.
# 2007 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights
reserved.Introduction
Crimean—Congo hemorrhagic fever (CCHF) is a severe,
potentially fatal disease in humans; it is caused by infection
with the CCHF virus (CCHFV).1 CCHF is described in about 30* Corresponding author. Tel.: +90 346 2581084;
fax: +90 346 2191284.
E-mail address: enginay@cumhuriyet.edu.tr (A. Engin).
1201-9712/$32.00 # 2007 International Society for Infectious Diseases.
doi:10.1016/j.ijid.2007.06.003countries, and it has the most extensive geographic distribu-
tion of the medically important tick-borne viral diseases.2
The average mortality rate is often cited at 30—50%. Mor-
tality rates of nosocomial infections are often much higher
than those acquired naturally through tick bites.1
CCHFV is a member of the Nairovirus genus of the family
Bunyaviridae.3 CCHF viruses are transmitted by Hyalomma
genus ticks, particularly by Hyalomma marginatum margin-
atum.2 Human beings become infected through tick bites, byPublished by Elsevier Ltd. All rights reserved.
Transient evoked otoacoustic emission test in CCHF 163crushing infected ticks, after contact with a patient with
CCHF during the acute phase of infection, or by contact with
blood or tissues from viremic livestock.1,3 The most impor-
tant clinical features are fever and hemorrhage.
Otoacoustic emissions (OAEs) have been suggested as a
sensitivemeasure of cochlear functionwith the potential for
preclinical detection of damage.4 The primary purpose of
otoacoustic emission (OAE) tests is to determine cochlear
status, specifically hair cell function. This information can
be used to: (1) screen hearing (particularly in neonates,
infants, or individuals with developmental disabilities); (2)
partially estimate hearing sensitivity within a limited range;
(3) differentiate between the sensory and neural compo-
nents of sensorineural hearing loss; and (4) test for func-
tional (feigned) hearing loss. The information can be
obtained from patients who are sleeping or even comatose
because no behavioral response is required.5,6 The normal
cochlea does not just receive sound; it also produces low-
intensity sounds called OAEs.7 OAEs are sounds caused by the
motion of the eardrum in response to vibrations from deep
within the cochlea and organ of Corti, and can be recorded in
the ear canal using a specialized microphone.8 There is
significant interest in the clinical usefulness of evoked otoa-
coustic emissions (EOAEs) for early identification of sensor-
ineural (cochlear) hearing loss that is undetectable by other
audiologic methods. OAEs are present in essentially all
healthy ears but are absent in ears with sensorineural
(cochlear) hearing loss of greater than approximately
30 dB.9,10
In this prospective study we have evaluated the cochlear
damage caused by CCHFV with the OAE test.
Materials and methods
We conducted a prospective analysis of 32 patients with a
diagnosis of confirmed CCHF infection; 13 healthy volunteer
adults acted as controls. The control group consisted of
volunteers from the Cumhuriyet University staff. CCHF
patients were also grouped for the presence of fever. Fever
was defined as the presence of body temperature (axillary)
38 8C.
Thirty-two patients diagnosed with CCHF infection and
followed up at the Department of Infectious Diseases and
Clinical Microbiology at Cumhuriyet University Hospital (an
800-bed teaching hospital) in the city of Sivas located in
central Anatolia, Turkey, between May and September of
2005, were included in this study. The diagnosis of CCHF
infection was based upon typical clinical and epidemiological
findings and serological tests with ELISA. Serum samples of
the patients were sent to the Virology Laboratory of Refik
Saydam Hygiene Central Institute, Ankara, Turkey for micro-
biological testing for CCHF virus infection. Anti-CCHF IgM and
IgG antibodies and CCHF viral antigen were tested in seraTable 1 TEOAE test results and fever exposure in the CCHF and
Study groups TEOAE test passed TEO
CCHF patients (N = 24) 14 10
Control group (N = 13) 12 1
TEOAE, transient evoked otoacoustic emission test; CCHF, Crimean—Cosamples of patients by ELISA. Twenty-five of 32 (78.1%) CCHF
patients had CCHF virus-specific IgM antibodies, and seven of
32 (21.9%) had CCHF virus antigen.
An otolaryngologist examined the patients to determine
any other otological manifestations that could impair the
OAE. Pure tone audiometry was performed in the patient’s
room and in a silence environment with a MAICO portable
audiometer and TDH 39 headphones. Those patients with
hearing loss greater than 30 dB and those having any other
otological manifestations that could impair the OAE were
excluded from the study. The ILO88 transient evoked otoa-
coustic emission test (TEOAE) V5 system (Otodynamics Ltd,
Hatfield, UK) was used for the study. TEOAE tests were
conducted on the same day as the pure tone test. The test
stimulus approximated 80.0 dB and the gain was 0.0 dB. Two
hundred and sixty click sweeps were sent to the ear and the
emissions were collected by a microphone in a probe. A
response at three frequencies of 3 dB or greater above the
noise floor with a minimum 70% reproducibility at each
frequency and 90% or greater stability was required for
passing the TEOAE test. An otolaryngological examination
and TEOAE test were performed in all patients with a suspi-
cion of CCHF infection before any medical treatment was
given. Those not serologically confirmed as a CCHF infection
were not included in the study. Pure tone audiometry and the
TEOAE test were performed in all of them.
The Mann—Whitney test was performed for the analysis of
age. The proportion of TEOAE test ‘fail’ results and sex were
analyzed with the Chi-square test. Fisher’s exact test was
performed for the effect of fever on the TEOAE test in our
study group.
Results
Of the CCHF patients, 18 (56.2%) were male and 14 (43.8%)
were female, and the mean age was 49.2  20.8 years. Six
(46.2%) in the control group were male and seven (53.8%)
were female, and the mean age of the healthy people was
47.6  7.1 years. There was no significant difference
between the study and control groups with regard to sex
and age ( p > 0.05).
Eight of 32 CCHF patients were excluded from the study
because of previous hearing loss greater than 30 dB; hence 24
CCHF patients with normal hearing were included in the
study. Fourteen of 24 CCHF patients (58.3%) with normal
hearing had a test result of ‘pass’ for the TEOAE test; 10 of 24
(41.7%) had a test result of ‘fail’. Twelve of 13 (92.3%) in the
control group had a ‘pass’ result for the TEOAE test; one of 13
(7.7%) received a ‘fail’. The proportion with a result of ‘fail’
for the TEOAE test in the CCHF patients was significantly
higher than in the control group ( p < 0.05).
Of the 24 CCHF patients, 17 were exposed to fever and
seven were not. Of those exposed to fever, 12 CCHF patientscontrol groups
AE test failed Exposed to fever No fever
17 7
0 12
ngo hemorrhagic fever.
164 A. Engin et al.passed the TEOAE test and five failed. Of those not exposed to
fever, two CCHF patients passed the TEOAE test and five
failed. We found no increase in the proportion of ‘fail’ of
TEOAE test related to fever in the study group. Table 1
summarizes the data for the 24 CCHF patients and 13 healthy
controls in our study.Discussion
In this study using the TEOAE test, we found that CCHF virus
infection may cause cochlear damage. We found no increase
in the proportion of failed TEOAE tests related to fever in
CCHF patients. There is a limitation that needs to be
addressed regarding the present study; this concerns the
case—control design.
CCHF is one of the viral hemorrhagic fever diseases. It was
first described in the Crimea in 1944 and given the name
Crimean hemorrhagic fever. In 1969, it was recognized that
the pathogen causing Crimean hemorrhagic fever was the
same as that responsible for an illness identified in 1956 in
the Congo, and linkage of the two place names resulted in the
current name for the disease and the virus.1,11 The virus
shows a wide geographic distribution and is regarded as a
public health threat in many regions of the world, including
Asia, Eastern Europe, the Middle East, and Africa, but poses
an impending threat also in non-endemic areas.2,12,13
Recently, CCHF has been endemic in our country and large
outbreaks have been seen in the service area of our training
hospital during the spring and summer seasons. The disease
has become an increasing and serious problem in the Middle,
Northern, and Eastern Anatolia regions of Turkey.14—16
General supportive therapy is the mainstay of patient
management in CCHF infection. Intensive monitoring to
guide volume and blood component replacement is
required.11 Ribavirin inhibits CCHF virus in vitro, but its
efficacy in clinical practice remains unconfirmed; it should
be noted that there is no evidence from randomized clinical
trials for the use of ribavirin to treat human CCHF virus
infections.1,2,17
The specific mechanisms underlying the pathogenesis of
the CCHF virus have not been clearly explained.1,18—20 Capil-
lary fragility is a common feature of CCHF, suggesting infec-
tion of the endothelium.1 Infection of the endothelium has an
important role in CCHF pathogenesis.21,22 The endothelium
can be targeted in two ways: indirectly by viral factors or
virus-mediated host-derived soluble factors that cause
endothelial activation and dysfunction, and/or directly by
virus infection and replication in endothelial cells.19,21
Endothelial damage contributes to hemostatic failure by
stimulating platelet aggregation and degranulation, with
consequent activation of the intrinsic coagulation cascade.2
Impairment of endothelial cell function can cause a wide
range of vascular effects that lead to changes in vascular
permeability or hemorrhage. It has been reported that
endothelial and hepatoma cells are susceptible to CCHFV
infection;20,23 however, to our knowledge, inadequate data
are available on the cellular targets and distribution of CCHF
virus in human tissues.
Otoacoustic emissions have been suggested as a sensitive
measure of cochlear function with the potential for precli-
nical detection of damage to the cochlea. They are consid-ered as two groups: spontaneous and evoked. Evoked OAEs
are divided into three subgroups, namely, transient evoked,
stimulus frequency, and distortion product. Among the var-
ious types of EOAEs, the transient evoked otoacoustic emis-
sions (TEOAE) and the distortion product otoacoustic
emissions (DPOAE) have gained special importance.5,24,25
In this study we have evaluated the cochlear damage caused
by CCHF with the TEOAE test.
A ‘fail’ of the TEOAE test can occur even before any
hearing loss. The proportion of TEOAE test ‘fail’ results in
the CCHF patients was significantly higher than in the control
group in our study. Fever may also impair OAE tests.26 How-
ever we found no increase in the proportion of failed TEOAE
tests related to fever in CCHF patients. In the literature,
there is no study on cochlear damage in CCHF infection, so
this is the first investigational study and further studies are
needed.
In conclusion, CCHF disease impairs cochlear function in
patients with or without fever. We recommend the monitor-
ing of the cochlea in all CCHF patients.
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